摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine

中文名称
——
中文别名
——
英文名称
N-cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine
英文别名
N-cyclohexyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4-amine;N-cyclohexyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine
N-cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine化学式
CAS
——
化学式
C16H21N3S
mdl
——
分子量
287.429
InChiKey
PVIRULZHKLRIFO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    66
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor
    摘要:
    We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D-2 receptor (D2R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D2R including NAMs with sub-mu M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i). (C) 2019 Published by Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2019.01.061
点击查看最新优质反应信息

文献信息

  • Green catalyst access to thieno [2, 3‐b] pyridines derivatives
    作者:Nawel Mehaoui、Souheyla Boudjema、Zahira Kibou、Noureddine Choukchou‐Braham、Abderrahim Choukchou‐Braham
    DOI:10.1002/jhet.4635
    日期:——
    benefits including a quicker reaction time, an easy set-up, and high yields. Spectroscopic data (IR, +H and 13C NMR spectra) have revealed the structural details of all target compounds. The catalyst was characterized by X-ray diffraction, BET and Fourier-transformed infrared spectroscopy. X-ray diffraction showed that PVW was correctly incorporated on an acid activated clays support. In comparison
    目前的研究重点是使用具有 Keggin 结构并负载在酸活化 (PVW/AAM) 上的钨钒磷酸杂多酸 H 4 PW 11 VO 40 ·8 H 2 O (PVW) 合成新取代的 Thieno [2, 3- b] 吡啶衍生物。建议的协议是一种简单、环保的方法,用于在无溶剂反应条件下合成从 3-cyano-2-aminothiopene 获得的 thieno [2,3-b] 嘧啶衍生物作为构建块。使用合成的 PVW/AAM 催化剂实现了取代的 Thieno [2, 3-b] 吡啶衍生物的优异产率 (60%–97%)。目前的工艺提供的好处包括更快的反应时间、简单的设置和高产率。光谱数据(IR,+ H 和13 C NMR 光谱)揭示了所有目标化合物的结构细节。通过X射线衍射、BET和傅里叶变换红外光谱对催化剂进行了表征。X 射线衍射表明 PVW 正确地结合在酸活化粘土载体上。与母体钨钒磷酸相比,PVW
  • IRAK INHIBITORS AND USES THEREOF
    申请人:Nimbus Iris, Inc.
    公开号:EP2663312B1
    公开(公告)日:2017-10-11
  • Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor
    作者:Tim J. Fyfe、Barrie Kellam、Shailesh N. Mistry、Peter J. Scammells、J. Robert Lane、Ben Capuano
    DOI:10.1016/j.ejmech.2019.01.061
    日期:2019.4
    We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D-2 receptor (D2R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D2R including NAMs with sub-mu M affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i). (C) 2019 Published by Elsevier Masson SAS. All rights reserved.
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇 7-溴噻吩并[3,2-d]嘧啶 7-溴噻吩并[3,2-D]嘧啶-4(1H)-酮 7-溴-噻吩并[3,2-d]嘧啶-4-胺 7-溴-4-氯噻酚并[3,2-D]嘧啶 7-溴-2-氯噻吩并[3,2-D]嘧啶